Reestablishment of active immunity against HBV graft reinfection after liver transplantation for HBV-related end stage liver disease.

Vaccination preventing HBV reinfection for OLT recipients is feasible. The strategy withdrawal of HBIG with induction of active immunity against hepatitis B is reasonable for long-term survivors of OLT; however, discontinuation nucleoside analogues should be cautious.